Abzu designed active and safe ASO and siRNA therapeutics.

A strategic partnership with Contera Pharma included ASO and siRNA therapeutic designs and target identification.

Contera Pharma is a Danish biotech company with an affiliate in Seoul, South-Korea developing innovative ASO and siRNA therapeutics to improve life for people suffering from neurological disorders.

Abzu designed active and safe ASO and siRNA therapeutics.

Your partner for precise and exceptional results.

Initially we supported a single researcher with expertise in RNA therapeutics to predict activity for ASO therapeutics. Later, we expanded our partnership to design siRNAs therapeutics and identify novel targets.

Abzu bioinformatician

A testament to innovation and collaboration.


Abzu’s explainable artificial intelligence technology and in-house RNA and data science capabilities was a key stepping stone for our R&D strategy to develop novel and innovative ASO and siRNA therapeutics.

Kenneth Vielsted Christensen, Chief Scientific Officer

Deepening disease and disease-target understanding.

We accelerated ASO and siRNA therapeutics design through parallel hypotheses testing of targets and individual drug properties.

This approach allows simultaneous exploration of multiple promising avenues — and with an additional understanding of the “why” behind biological mechanisms — is a leap forward in drug discovery.

Abzu multiplies the pace at which potential ASO and siRNA therapeutics can be designed and evaluated, cutting down on both time and financial investment required.


This partnership made headlines.

March 22, 2022


Abzu and Contera Pharma expand strategic partnership to add target identification to RNA therapeutic design platform.

Korea IT Times
July 9, 2021


Contera Pharma, a subsidiary of Bukwang Pharm, partners with Abzu to develop new treatment for people suffering from neurological disorders

July 7, 2021


Contera Pharma vil i højere grad rykke forskning internt med nyt samarbejde

July 7, 2021


Abzu and Contera Pharma partner to design RNA therapeutics for rare diseases with explainable AI.

Less data, more discovery.

Make the most out of every piece of information.

Contrary to the data-heavy demands of black-box AI, our technology thrives on minimal data. This efficiency not only accelerates the discovery process, but also reduces your barrier to entry to develop new, innovative drugs.

Share this case study.

Want more details?

A partnership protects your targets and designs, ensuring a swift and unobstructed path to market.

Through an exclusive agreement, Abzu guarantees a commitment to confidentiality, focus, and unparalleled innovation. Maximize your investment and results with a partnership in drug discovery.

Accelerate your drug discovery with best-in-class in silico solutions.

Read more case studies from Abzu.

Abzu’s QLattice uniquely identified key “partner” genes involved in skin spaceflight response, a new discovery for how spaceflight damages skin.
Understanding how bears can hibernate without developing blood clots or muscle atrophy can help humans prepare for the future of space travel.
Stratifying patients at pretreatment by answering the question: Can we distinguish which patients will respond to OMO-103 treatment at baseline?

Subscribe for
notifications from Abzu.

You can opt out at any time. We’re cookieless, and our privacy policy is actually easy to read.